{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shalabi H"],"funding":["Intramural NIH HHS","NCI NIH HHS","NIH HHS"],"pagination":["451-463"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9353146"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["140(5)"],"pubmed_abstract":["Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute lymphoblastic leukemia (B-ALL), we report on our phase 1 dose-escalation study of a novel murine stem cell virus (MSCV)-CD19/CD22-4-1BB bivalent CAR T-cell (CD19.22.BBζ) for children and young adults (CAYA) with B-cell malignancies. Primary objectives included toxicity and dose finding. Secondary objectives included response rates and relapse-free survival (RFS). Biologic correlatives included laboratory investigations, CAR T-cell expansion and cytokine profiling. Twenty patients, ages 5.4 to 34.6 years, with B-ALL received CD19.22.BBζ. The co"],"journal":["Blood"],"pubmed_title":["CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR."],"pmcid":["PMC9353146"],"funding_grant_id":["S10 OD027023","ZIA BC011823","75N91019D00024","ZIA BC011923"],"pubmed_authors":["Silbert S","Su A","Achar S","Shalabi H","Little L","Steinberg SM","Taylor N","Ahlman M","Inglefield J","Toledo-Tamula MA","Chien CD","Goldberg S","DeDe K","Highfill SL","Schneider D","Shahani SA","Fry TJ","Mackall CL","Wang Y","Martin S","Altan-Bonnet G","Benzaoui M","Panch S","Pouzolles M","Molina JC","Shah NN","Lee DW","Wang HW","Foley T","Ligon JA","Qin H","Yuan CM","Yates B","Wolters PL","Stroncek D"],"additional_accession":[]},"is_claimable":false,"name":"CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.","description":"Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute lymphoblastic leukemia (B-ALL), we report on our phase 1 dose-escalation study of a novel murine stem cell virus (MSCV)-CD19/CD22-4-1BB bivalent CAR T-cell (CD19.22.BBζ) for children and young adults (CAYA) with B-cell malignancies. Primary objectives included toxicity and dose finding. Secondary objectives included response rates and relapse-free survival (RFS). Biologic correlatives included laboratory investigations, CAR T-cell expansion and cytokine profiling. Twenty patients, ages 5.4 to 34.6 years, with B-ALL received CD19.22.BBζ. The co","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-07-14T19:34:10.329Z","creation":"2025-04-05T16:05:27.171Z"},"accession":"S-EPMC9353146","cross_references":{"pubmed":["35605184"],"doi":["10.1182/blood.2022015795"]}}